Background: The breast and ovarian cancer suppressor BRCA1 is essential for cellular responses to DNA damage [1] . It heterodimerizes with BARD1 to acquire an E3 ubiquitin (Ub) ligase activity that is often compromised by cancer-associated mutations [2] . Neither the significance of this activity to damage responses, nor a relevant in vivo substrate, is clear. Results: We have separated DNA-damage responses requiring the BRCA1 E3 ligase from those independent of it, using a gene-targeted point mutation in vertebrate DT40 cells that abrogates BRCA1's catalytic activity without perturbing BARD1 binding. We show that BRCA1 ubiquitylates claspin, an essential coactivator of the CHK1 checkpoint kinase, after topoisomerase inhibition, but not DNA crosslinking by mitomycin C. BRCA1 E3 inactivation decreases chromatin-bound claspin levels and impairs homology-directed DNA repair by interrupting signal transduction from the damage-activated ATR kinase to its effector, CHK1. Conclusions: Our findings identify claspin as an in vivo substrate for the BRCA1 E3 ligase and suggest that its modification selectively triggers CHK1 activation for the homologydirected repair of a subset of genotoxic lesions. This mechanism unexpectedly defines an essential but selective function for BRCA1 E3 ligase activity in cellular responses to DNA damage.
Introduction
There is abundant evidence that the breast and ovarian tumor suppressor, BRCA1, has essential functions in diverse cellular processes implicated in the DNA damage response [1] . How BRCA1 mediates these functions remains unclear. Much attention has focused on the E3 ubiquitin ligase activity acquired when BRCA1 heterodimerizes through its aminoterminal RING domain with an evolutionarily conserved RING partner, BARD1 [3] . Deleterious missense mutations affecting the BRCA1 RING domain can be found in familial breast cancers that do not vitiate BARD1 binding but can nevertheless abolish E3 ligase activity [2, 4] , suggestive of its functional importance. However, a BRCA1 point mutation abolishing E3 activity does not impair ionizing radiation sensitivity or the repair of endonuclease-induced DNA breaks by homologous recombination [5] . Furthermore, mice harboring the mutation do not develop breast cancers [6] . On the other hand, inactivation of BRCA1 E3 ligase activity can derepress heterochromatic satellite DNA transcription, an event that has been linked to abnormalities in DNA repair and mitosis [7] . Thus, if and how BRCA1's E3 ligase activity is necessary for the cellular response to DNA damage remains uncertain.
BRCA1 has been implicated in several processes essential for the cellular response to DNA lesions repaired by homologous recombination [1] . One key step involves activation of the checkpoint kinase CHK1, an essential component of the damage response machinery in vertebrates. Phosphorylation of CHK1 occurs on chromatin. The phosphorylated CHK1 is released from chromatin and the dissociation is required for checkpoint activation [8] . BRCA1 has been implicated in CHK1 activation via ATR and claspin. ATR-phosphorylated claspin forms a trimolecular complex containing BRCA1 and CHK1 [9] . Complex formation is essential for CHK1 phosphorylation and activation [9] ; in turn, activated CHK1 mediates checkpoint enforcement as well as DNA repair by homologous recombination [10, 11] , through modulation of the interaction between BRCA2 and the recombinase RAD51 [12, 13] . However, the mechanism through which BRCA1 controls the claspin-CHK1 axis, and in particular, whether its E3 ligase activity is required, is not known.
Here, we have used ''hit-and-run'' gene targeting to create a DT40 cell line carrying a single mutation in BRCA1, replacing Val26 in the RING domain with Ala (V26A). The V26A mutation abrogates E3 ligase activity without affecting the interaction between BRCA1 and BARD1. Unexpectedly, E3 inactivation reveals a mechanism distinguishing DNA damage responses that require BRCA1's catalytic activity, from those independent of it. Whereas the BRCA1 E3 ligase is essential for chromatin association of claspin and CHK1 activation when a topoisomerase poison, camptothecin (CPT), blocks DNA replication, it is dispensable for these events after replication blockage by a DNA crosslinker, mitomycin C (MMC). In turn, downstream responses regulated by CHK1, including RAD51 foci formation, sister chromatid exchange, and cellular sensitivity, are selectively impaired after exposure to CPT, but not MMC. Thus, our work suggests that the BRCA1 E3 ligase selectively triggers claspin-CHK1 activation, providing the first example of an E3-dependent mechanism underlying an essential function for BRCA1 in the cellular response to DNA damage.
Results and Discussion
BRCA1 has been implicated in the cellular response to DNA double-strand breaks leading to their resolution by homology-directed repair (HDR) [1] . We used avian DT40 cells, a well-established model widely used to study the role of BRCA1 in this response [14] [15] [16] , to determine the functional *Correspondence: arv22@cam.ac.uk significance of BRCA1 E3 ligase activity. In mammalian BRCA1 homologs, Ile26 in the RING domain is implicated in binding to E2 ubiquitin conjugating enzymes [2] . Its substitution by Ala abolishes BRCA1's E3 ligase activity without affecting heterodimerization to BARD1 [2] . Val26 in the avian RING domain conservatively replaces Ile26 in its mammalian counterparts, reflecting their strong evolutionary conservation (see Figure S1A available online). We cloned the RING domains of avian BRCA1 and BARD1 from a DT40 complementary DNA (cDNA) library and introduced the Val26Ala (V26A) point mutation by site-directed mutagenesis. When cotransfected into 293T cells with the avian BARD1 RING domain, the V26A mutant form of the GgBRCA1 RING domain still binds to the BARD1 RING domain ( Figure S1B ) but fails to catalyze the transfer of ubiquitin in vitro ( Figure S1C ). Thus, replacement of Val26 with Ala in avian BRCA1 abolishes the E3 ligase activity of the RING domain but not its interaction with BARD1. This confirms that avian Val26 is functionally cognate with Ile26 in mammalian BRCA1. Figure S1D shows the gene-targeting strategy used to create a DT40 cell line carrying a Val26-Ala substitution in the Figure S1 and Table S1 . endogenous BRCA1 gene. The targeting vector carries a blasticidin or neomycin resistance cassette flanked by loxP sites for the CRE recombinase, enabling recycling of the resistance marker by CRE transfection between sequential rounds of targeted integration. Homozygous Val26-Ala replacement was confirmed by amplification of the targeted BRCA1 genomic locus using the indicated primers ( Figure S1D ), by a diagnostic restriction digest with BsrDI ( Figure S1E ) and by nucleotide sequencing (data not shown). Western blotting of extracts from BRCA1 wild-type (WT) or BRCA1 V26A/V26A (V26A) cells confirmed that the WT and mutant BRCA1 proteins were expressed at similar levels ( Figures S1F and S1G) . Thus, in accord with previous reports [14, 15] , BRCA1 E3 ligase is dispensable for the viability and growth of DT40 cells.
BRCA1 has been implicated in the cellular response to agents that inflict DNA lesions repaired by HDR. These include the topoisomerase I poison, camptothecin (CPT), which triggers DNA breakage at replication forks [17] , or the DNA crosslinking agent, mitomycin C (MMC), which creates intrastrand lesions as well as interstrand crosslinks that prevent the movement of replication forks [18] . We exposed WT or V26A cells to increasing doses of CPT or MMC for 40 hr before measuring cell viability ( Figures 1A and 1B) . V26A cells exhibit enhanced sensitivity to CPT, but not MMC. This raises the unexpected possibility that BRCA1 E3 ligase activity is selectively required for certain cellular responses leading to the repair of certain types of DNA lesions by HDR, but not others.
Two key cellular events report on the integrity of HDR in DT40 cells. First, inactivating mutations in known HDR proteins, including BRCA1 deletions [14] , suppress the accumulation of the recombination enzyme RAD51 in nuclear foci at sites of DNA repair. Second, such mutations also inhibit the spontaneous or genotoxin-induced exchange of genetic material between sister chromatids (sister chromatid exchange, SCE), a direct measure of HDR [19] . Consistent with their enhanced sensitivity to CPT, V26A cells exhibit a diminution in their ability to form RAD51 foci in response to these agents, when compared to WT cells ( Figures 1C and 1D ). Interestingly, such a defect is not apparent when these cell lines are exposed to MMC, consistent with their lack of sensitivity to this genotoxin. Similarly, the V26A mutation in BRCA1 also suppresses SCE formation induced by CPT, but not MMC (Figures 1E and 1F ; Table S1 ) even though spontaneous SCE formation in V26A cells is slightly greater than in WT controls. Because SCE formation is a direct measure of crossover events mediated by HDR [19] , our findings indicate that BRCA1 E3 activity is dispensable for the execution of DNA repair by this pathway in response to spontaneously arising, or MMC-induced, DNA damage. Instead, they reveal a more selective requirement for BRCA1's catalytic activity in the repair of CPT-induced lesions by HDR.
To identify substrates for BRCA1 E3 ligase relevant to this dichotomous role, we examined claspin, a critical coactivator of the damage-activated checkpoint kinase CHK1 necessary for HDR [9, 20] . BRCA1 forms a trimolecular complex with CHK1 and claspin through its direct binding to claspin, although how it promotes their activation remains unknown [9] . We therefore tested whether claspin itself might be an unrecognized target for modification by the E3 ligase activity of BRCA1. A myc-tagged fragment spanning residues 1 to 772 of BRCA1, which forms an active E3 ligase enzyme when cotransfected with BARD1 [3] , can conjugate hemagglutinin (HA)-tagged ubiquitin (Ub) to FLAG-claspin ( Figure 2A ). This activity is abrogated by omission of either BARD1 or BRCA1, or expression of the BRCA1 I26A mutant, confirming that claspin modification requires the heterodimeric E3 enzyme. To identify the regions of claspin that can undergo modification, we first tested four fragments each of about 350 amino acids dividing claspin at well-established domain boundaries [21] . The N-terminal fragment spanning residues 1-331 was highly ubiquitylated compared to other fragments (data not shown). The copurified recombinant BRCA1/BARD1 heterodimeric complex is able to ubiquitylate this N-terminal claspin fragment in an in vitro Ub ligation assay ( Figure 2B ), indicating that it is a candidate substrate for the BRCA1 E3 ligase.
Many candidate substrates for the BRCA1 E3 ligase have been identified in vitro, but none has so far been confirmed in cellular studies [22] . We therefore asked whether claspin ubiquitylation could be detected in cells and whether this modification reflected the dichotomous requirement we have identified for BRCA1 E3 ligase activity in the response to CPT but not MMC. We exposed WT or V26A cells to these agents before cell lysates were immunoprecipitated with an antibody to conjugated ubiquitin (FK2), followed by western blotting with an anti-Ggclaspin antibody. Strikingly, the Ub conjugation of endogenous claspin was induced in response to CPT (but not MMC) in WT (but not V26A) cells ( Figure 2C ). One predominant Ub-conjugated claspin species is observed, consistent with our overexpression experiments in 293T, in which FLAG-claspin was modified with HA-ubiquitin (Figure 2A ). These observations suggest that the BRCA1 E3 ligase does indeed selectively ubiquitylate claspin in cells exposed to CPT but not MMC, and provide a first example of in vivo substrate ubiquitylation by this enzyme during a biological process.
We identified the sites of BRCA1/BARD1-mediated ubiquitin conjugation in the N-terminal claspin fragment spanning residues 1-331 by mass spectrometry (Figures 3A and 3B ; Table  S2 ). Analysis of tryptic digests of this claspin fragment after in vitro ubiquitylation by BRCA1/BARD1 revealed four potential conjugation sites (Table S2) . Covalent linkage of a di-Gly motif introduced by substrate ubiquitylation at Lys60 and Lys96 was unambiguously identified in two independent fragment-ion spectra each, whereas Lys89 and Lys105 were identified in only one spectrum each ( Figures 3A and 3B ). Moreover, a protein sequence alignment of residues 1-331 of claspin across multiple species that also have a known BRCA1 ortholog demonstrated that Lys60 was found in a region of high sequence conservation that also contained additional conserved basic residues. In contrast, the sequence surrounding Lys96 is less well conserved ( Figure 3C ). Taken collectively, these findings suggest that Lys60 represents an evolutionarily conserved modification site on claspin, and that the protein may also be modified by Ub conjugation at additional Lys residues in its N-terminal region.
In fact, three conserved lysines (Lys54, Lys55, and Lys57) occur in the six residues N-terminal to Lys60. Because sitespecific ubiquitylation becomes promiscuous if the preferred Lys target is absent but a neighboring alternative acceptor lysine is present [23] , we created a mutant form of claspin (NT-KR) in which all four Lys residues at positions 54, 55, 57, and 60 were changed to Arg. WT or NT-KR mutant forms of claspin were cotransfected into 293T cells with BRCA1/ BARD1 in the presence of HA-ubiquitin. Ub conjugation to WT claspin was evident when BRCA1/BARD1 were coexpressed, and decreased by expression of the BRCA1 I26A mutant ( Figure 3D) . Moreover, the NT-KR claspin mutant shows reduced modification compared to the WT form. Together, these data suggest that BRCA1/BARD1 conjugates Ub to Lys60 and adjacent residues in the N-terminus of claspin.
Because CHK1 is phosphorylated on chromatin when forming a complex with BRCA1 and claspin, we tested whether Figure S3 and Table S2. claspin ubiquitylation affects its accumulation on chromatin. To do this, we compared the levels of WT or NT-KR mutant claspin in the soluble (S1+S3) or chromatin-bound (P3) fractions of nuclear extracts prepared from 293T cells exposed to these agents ( Figure 4A ). WT claspin is detected in both the soluble and chromatin-bound protein fractions of nuclear extracts. In contrast, NT-KR mutant claspin does not accumulate in the chromatin-bound protein fraction in cells exposed to CPT. Indeed, a similar difference is observed when the levels of claspin were measured in WT or V26A cells treated with CPT or MMC ( Figure 4B ). Claspin levels in the soluble fraction are similar in both cell types, before (2) and after exposure to CPT or MMC, with a slight reduction in V26A cells exposed to CPT (compare lanes 2 and 3 with 5 and 6 in row 1). In the chromatin-bound fraction, claspin expression in untreated V26A cells, or even in V26A cells exposed to MMC, is similar to the levels found in WT cells. Remarkably, however, in the chromatin-bound protein fraction prepared from V26A cells exposed to CPT, claspin is specifically diminished in comparison to WT controls (compare lanes 2, 5, in row 4) . Interestingly, the diminution in chromatin-bound claspin after CPT exposure is not accompanied by a reduction in its retention time measured by fluorescence recovery after photobleaching (FRAP, Figures S2A-S2C) . Instead, we observe a reduction in the half-life of NT-KR mutant claspin relative to the WT ( Figures  S2D and S2E) . Together, these results suggest that ubiquitylation of claspin by BRCA1/BARD1 is required for its accumulation in the chromatin-bound protein fraction in response to CPT and may exert this effect via the control of protein stability.
We therefore analyzed the effect on DNA-damage signaling of decreased chromatin-bound claspin levels in V26A cells exposed to CPT. We first investigated the steps leading to activation of the ataxia and Rad3-like (ATR) kinase, because claspin is known to coactivate CHK1 in an ATR-dependent manner [9, 20] . We find that the phosphorylation of MCM2 at Ser108, a known target for ATR phosphorylation after DNA damage [24] , is induced above predamage levels after the exposure of WT cells to CPT or MMC ( Figure 4C, lanes 2 and 3) . MCM2 S108 phosphorylation was elevated even in undamaged V26A cells and was not greatly increased after CPT or MMC exposure. This may reflect that endogenously arising DNA lesions in dividing V26A cells (marked by the increased basal level of SCE formation (Table S1 ; Figure 1F) constitutively elevate the resting level of ATR-dependent checkpoint activation. Nevertheless, these findings suggest that BRCA1 E3 inactivation does not prevent ATR-activated phosphorylation of MCM2 per se.
In contrast, the phosphorylation of CHK1, an evolutionarily conserved and essential component of the machinery for checkpoint enforcement and DNA repair by HDR [10, 13] , is selectively compromised after CPT exposure by the V26A mutation in BRCA1. ATR phosphorylates CHK1 on residues Ser317 and Ser345 [10, 25] . These modifications accompany and are essential for CHK1 activation mediated by ATR [10, 25] and are therefore used as surrogate markers for this event [25] . Although MMC triggers CHK1 modification on Ser345 in V26A as well as WT cells ( Figure 4C , lanes 3 and 6), phosphorylation of this Ser residue is selectively impaired in V26A cells after exposure to CPT (compare lanes 2 and 5). Thus collectively, our observations indicate that inactivation of the E3 ligase activity of BRCA1 causes a specific failure in signal transmission from ATR to CHK1 in response to CPT, but not MMC.
CHK1 activation triggered by DNA damage occurs on chromatin [8] . Claspin forms a trimolecular complex with BRCA1 and CHK1 that is essential for CHK1 activation [9] , and its turnover is reported to regulate CHK1 activation during recovery from damage-induced G2 arrest [26, 27] . In this light, our findings suggest a mechanism ( Figure 4D ) wherein ubiquitin conjugation to claspin by the BRCA1 E3 ligase promotes efficient CHK1 activation by maintaining chromatin-bound claspin levels after replication blockage triggered by CPT but not MMC. In turn, activated CHK1 mediates checkpoint enforcement [10] as well as DNA repair by homologous recombination, through modulation of the interaction between BRCA2 and the recombinase, RAD51 [12, 13] . Thus, our results suggest a novel role for claspin ubiquitylation by BRCA1 E3 ligase activity in selectively promoting the homology-directed repair of a subset of genotoxic lesions.
Why the claspin-CHK1 axis should require BRCA1 E3 ligase activity in response to CPT but not MMC is presently unclear. CPT traps a reversible, cleavable DNA structure by inhibiting the religation step during topoisomerase I-catalyzed reactions [28] ; the reversible complex is then converted into irreversible strand breaks upon encounter with the machinery for DNA replication. MMC triggers intrastrand lesions as well as DNA crosslinks, which block DNA replication forks; strand breakage accompanies their repair [18] . Thus, both genotoxins induce lesions that block DNA replication and whose repair by homologous recombination involves strand-break intermediates. However, there is insufficient knowledge to speculate what may distinguish these lesions or repair intermediates structurally to explain the differential requirement for BRCA1 activity in their resolution. Intriguingly, we find that V26A mutant cells are selectively more sensitive than their WT counterparts to the effect of several drugs that inhibit topoisomerase I (CPT, SN38) as well as topoisomerase II (doxorubicin, etoposide), but not to MMC (Figures S3A-S3E) . Moreover, V26A mutant cells fail to activate CHK1 Ser345 phosphorylation in response to topoisomerase inhibitors at doses that suffice to evoke this response in WT cells (Figure S3F) , further supporting the notion that BRCA1 E3 ligase activity is required for CHK1 activation in response to a subset of genotoxic lesions.
Our demonstration that BRCA1 E3 ligase activity is required for the response to some, but not all, genotoxic lesions provides new functional insight apposite to recent work concerning BRCA1's biological role. Recent reports suggest that the murine BRCA1 point mutation I26A, functionally analogous to the avian V26A mutation used here, neither affects ionizing radiation sensitivity, nor the repair of endonuclease-induced DNA breaks by homologous recombination [5] . Furthermore, mice harboring this mutation do not develop breast cancers [6] . However, a different BRCA1 point mutation that abolishes both E3 ligase activity and BARD1 binding potentiates cellular sensitivity to poly-ADP ribose polymerase (PARP) inhibition and cisplatin, and mice carrying this mutation do develop breast cancer [29] . Notably, at least some of the BRCA1 missense mutations found in familial breast cancer patients abolish E3 ligase activity without impairing BARD1 binding [4] , like the V26A mutation used in our work, but in contrast to the murine I26A mutation. Moreover, we find that overexpression of the NT-KR mutant of claspin in human cells depleted of the endogenous WT protein by RNAi has a modest effect on CPT sensitivity but does not affect sensitivity to MMC ( Figures S4A-S4C) , consistent with the results reported here. Thus, in light of the possible differences between model systems and species, further exploration of the selective requirement for BRCA1 E3 activity in the response to certain forms of DNA damage that we have identified in this work seems warranted.
Our observations, if confirmed in human cancer cells, could have potential implications for the treatment of BRCA1-deficient familial cancers in which mutations selectively impair E3 ligase activity without creating a nullizygous phenotype [4] . Our findings suggest that there may be benefit in such a setting from treatment with CPT but not MMC. We speculate that this may also apply to some of the w10% of sporadic cancers belonging to the basal-like group, which exhibit certain phenotypic characteristics suggestive of impaired but not absent BRCA1 deficiency [30, 31] . These hypotheses warrant further investigation.
Experimental Procedures
Cell Culture 293T cells were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic agent at 37 C. DT40 cells were maintained in RPMI-1640 medium (GIBCO-BRL) supplemented with 10 25 M b-mercaptoethanol, 10% fetal calf serum (FCS), 1% antibiotic-antimycotic agent, and 5% chicken serum (GIBCO-BRL) at 39 C.
Plasmids cDNA of GgBRCA1 (1-222) and GgBARD1 (1-159) were amplified by PCR from a cDNA pool generated with SuperScriptÒ III First-Strand Synthesis System (Invitrogen) with Pfx DNA polymerase (Invitrogen) and subcloned into p3X-FLAG-CMV or pcDNA3-myc vectors. For the purification of GgBRCA1 (1-300), cDNA was amplified by PCR as above and subcloned into pGEX-4T3 vector in frame with FLAG amino-terminal tag. For cDNA of GgBRCA1 V26A, both 1-222 and 1-300, were obtained from the cDNA pool derived from V26A cells with same method outlined above. Myc-tagged HsBRCA1(1-772), HsBARD1, His-tagged HsBARD1, and HA-tagged-HsUbiquitin were described previously [32] . cDNA of Hsclaspin was purchased from Geneservice and PCR was performed to ligate into p3XFLAG-CMV or pcDNA3.1-Hygro (in frame with NH2-terminal EGFP tag) vectors. The missense mutant of claspin (NT-KR) was generated by site-directed mutagenesis. Truncation mutant of claspin (1-331) was generated by introducing an in-frame NotI or BamHI site and a stop codon in the appropriate position by site-directed mutagenesis followed by digestion with either NotI or BamHI to remove the fragment.
Gene Targeting
The sequences of the oligonucleotide primers used here are in Supplemental Experimental Procedures. The homologous sequences of avian BRCA1 used for targeting were isolated by PCR from DT40 genomic DNA using primers LA F1, LA R1 for left homology arm and RA F1, RA R1 for right homology arm and cloned into a targeting vector bearing either a neomycin or blasticidin resistant cassette. The V26A mutation and BsrDI diagnostic (silent mutation) restriction site were generated by site-directed mutagenesis using the Quickchange Site-Directed Mutagenesis Kit (Stratagene). Heterozygous cells were subjected to a second round of targeting and homozygous mutant cells were screened by PCR using primer DV26A and LAR1 ( Figure 2A ) followed by digestion with BsrDI.
Antibodies
The rabbit polyclonal anti-GgBRCA1 antibodies were raised against the recombinantly expressed N-terminal 300 amino acids of avian BRCA1 protein. Anti-Ggclaspin antibody was generously provided by Dr. David Gillespie (Beatson Institute for Cancer Research, Glasgow). Other antibodies used in this study were as follows: anti-FLAG (M2) and anti-b-actin (AC-15) antibodies (Sigma); anti-Myc (9E10), anti-ATR (N-19), and anti-CHK1 (G-4) antibodies (Santa Cruz Biotechnology); anti-phospho-ATM (S1981) and anti-phospho-CHK1 (S345) (Cell Signaling Technology); anti-RAD51 (Ab-1) (Calbiochem); and anti-HA (12CA5) (Roche). All western blotting or immunofluorescence reagents were used at the dilutions recommended by the manufacturers.
Drug Sensitivity Assay
Cells were plated into 96-well plates at a density of 8,000 cells per well. Different doses of mitomycin C (Sigma) and camptothecin (Sigma) were added, and the plates were incubated at 39 C for 40 hr. Cell Titer-Blue reagents (Promega) were added to each well of the 96-well plate according to the manufacturer's guidelines. The plates were incubated at 37
C for approximately 1-2 hr in a humidified 5% CO 2 atmosphere. The intensity of Titer-Blue signal, and thus a fraction of viable cells per well was determined using the Fusion Plate Reader (Perkin Elmer/Packard) at A590 nm. Each experiment was done in quadruplicate.
Western Blots and Immunoprecipitation 293T cells were transfected by a standard calcium chloride method. Thirtysix hr after transfection, cells were lysed with 0.5% NP-40 lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM DTT, 1 mM Na 3 VO 4 , complete protease inhibitor cocktail [Roche] , and 1 mM PMSF). To detect ubiquitylation in vivo, we lysed cells with 1% SDS lysis buffer (1% SDS, 0.5 mM EDTA, 1 mM DTT and 50 mM Tris HCl pH 7.5) at 100 C for 10 min. After collecting supernatant, the lysate was diluted 10 times in NP40 lysis buffer for immunoprecipitation. Immunoprecipitates were washed extensively in NP-40 lysis buffer and resolved by SDS-PAGE. For fractionation, cells were lysed with buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.034 M sucrose, 10% glycerol, 1 mM DTT, 100 mM PMSF, complete protease inhibitor cocktail [Roche], 5 mM Na 3 VO 4 , 10 mM NaF, 1 mM Okadaic acid) with 0.1% Triton X-100 for 5 min on ice. Cells were centrifuged at 1300 3 g for 4 min and supernatant collected (S1). S1 was further clarified by high speed centrifugation. The nuclei (P1) were washed in buffer A, then lysed by buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, PMSF, complete protease inhibitor cocktail [Roche], 5 mM Na 3 VO 4 , 10 mM NaF, 1 mM Okadaic acid) for 1 min on ice. Nuclei were centrifuged at 1,700 3 g for 4 min. Soluble nuclear fraction (S3) was collected. The insoluble chromatin pellet was then resuspended in buffer A with 1 mM CaCl 2 and 0.2 U micrococcal nuclease, incubated at 37 C for 10 min. Chromatin fraction (P3) was collected by high speed centrifugation.
Immunofluorescence Microscopy
To detect RAD51 foci, we spun cells onto glass slides by using a cytocentrifuge (Shandon). After drying for 5 min, cells were fixed with 4% paraformaldehyde for 10 min at room temperature. Samples were solubilized with 0.2% Triton X-100 for 5 min and blocked with 3% BSA in 1xPBS, 0.1% Tween-20, 0.1%Triton X-100 (PBST) for 15 min. Cells were then probed with a rabbit polyclonal anti-RAD51 antibody diluted 1:1,000 for 30 min.
Sister Chromatid Exchange Assay
The sister chromatid exchange assay was performed as described previously [33] . Briefly, cells were cultured for two cell cycles in the presence of 10 mM bromodeoxyuridine and with or without 10 nM camptothecin (CPT) and 150 nM mitomycin C (MMC) for the second cell cycle. Cells were pulsed with 100 ng/ml colcemid for 3 hr before harvest. Cells were hypotonically swollen in 75 mM KCl for 20 min at room temperature before fixation in freshly prepared Carnoy's solution (methanol: acetic acid, 3:1) for 30 min at room temperature. Fixed cells were dropped onto slides, dried at 50 C for 20 min and then incubated for 20 min in 10 mg/ml Hoescht-33258 (Sigma), diluted in 0.05 M sodium phosphate buffer, pH 6.8 at room temperature. Slides were irradiated with UV-A (365 nm) for 90 min and then incubated in prewarmed 2X SSC for 1 hr at 62 C. Slides were stained with freshly prepared Leishman's stain (Sigma) (diluted 1:3 in 0.05 M sodium phosphate buffer, pH 6.8) for 2 min. Slides were dried and mounted with Eukitt Mounting Media (Electron Microscopy Sciences) under a coverslip. Cells in metaphase were visualized with a 100X objective on a Zeiss Axioskop 2 microscope and 50 spreads scored blind to the observer.
Protein Purification GST-FLAG-GgBRCA1 (1-300, WT, and V26A) and GST-FLAG-claspin 1-331 were purified from BL21/DE3 bacterial cells following isopropyl-L-thio-B-Dgalactopyranoside (IPTG) induction as previously described [32] . Purification of His-UbcH5c and His-BARD1 was previously described [32] . Purification of His-BRCA11-304 and His-BARD11-320 as a RING heterodimer was performed as previously described [32] . Rabbit E1 (Affiniti) and mammalian ubiquitin (Affiniti) were purchased commercially.
Ubiquitin Ligation Assay In Vitro
The procedure used for the in vitro ubiquitin ligation assay was performed as previously described [32] with a reaction mixture (30 AL) that contained 50 mmol/L Tris-HCl (pH 7.5), 5 mmol/L MgCl 2 , 2 mmol/L ATP, 0.6 mmol/L DTT, 1 mg mammalian ubiquitin, 40 ng E1, 0.3 mg UbcH5c, 1 mg His-BRCA11-304/His-BARD11-320, and 1 mg of GST-FLAG-claspin 1-331. The ubiquitylation products were detected by immunoblotting with the indicated antibodies.
Preparation of Samples for Liquid Chromatography-Tandem Mass Spectrometry
After in vitro ubiquitin ligation, samples were resolved by SDS-PAGE. Gels were silver stained and excised spots were enzymatically cleaved in gel as previously described [34] . Each spot was reduced with 10 mM DTT at 56 C for 30 min and alkylated with 50 mM iodoacetamide (Sigma, Buchs, Switzerland) in the dark for 30 min followed by enzymatic cleavage with 2 mg Trypsin (Promega).
LC-MS/MS Analysis
The samples were analyzed on a LTQ Orbitrap XL mass spectrometer (MS; Thermo-Fisher Scientific, Bremen, Germany), which was connected online to a nanoelectrospray ion source (Thermo-Fisher Scientific, Bremen, Germany). Peptide separation was carried out using an Eksigent Tempo nano LC 1D+ System (Eksigent Technologies, Dublin, CA, USA) equipped with a RP-HPLC column (75 mm 3 15 cm) packed in-house with C18 resin (Magic C18 AQ 3 mm; Michrom BioResources, Auburn, CA, USA) using a linear gradient from 96% solvent A (0.15% formic acid, 2% acetonitrile) and 4% solvent B (0.15% formic acid, 98% acetonitrile) to 25% solvent B over 40 min at a flow rate of 0.3 ml/min. We injected 4 ml of each sample per liquid chromatography-tandem mass spectrometry (LC-MS/MS) run for analysis. After every two samples, a peptide mixture containing 200 fmol of [Glu1]-Fibrinopeptide B human (Sigma, Buchs, Switzerland) was analyzed by LC-MS/MS to constantly monitor the performance of the LC-MS/MS system. Acquired MS2 scans were searched against the UniProtKB/Swiss-Prot protein database (release v56.9) using the Sorcerer-SEQUESTÒ v4.0.4 search algorithm, which was run on the SageN Sorcerer (Thermo Electron). In silico trypsin, digestion was performed after lysine and arginine (unless followed by proline) tolerating two missed cleavages in fully tryptic peptides. Allowed monoisotopic mass error for the precursor ions was 50 ppm. A fixed residue modification parameter was set for carboxyamidomethylation (+57.021464 Da) of cysteine residues. Oxidation of methionine (+15.99492 Da) and ubiquitylation (+114.042923 Da) of lysine residues were set as variable residue modification parameter. For scoring, a maximum of two missed cleavages were considered. Search results were evaluated on the Trans Proteomic Pipeline (TPP v4.02).
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